Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
Conclusions
Patients had poor clinical outcomes with a median OS of <1 year and rwPFS of approximately 7 months, highlighting the significant unmet medical need in pretreated recurrent/advanced endometrial cancer patients. Novel therapies with potential to improve PFS and OS over conventional therapies could provide significant clinical benefit.
Source: BMJ Open - Category: General Medicine Authors: Zhang, J., Kelkar, S. S., Prabhu, V. S., Qiao, Y., Grall, V., Miles, N., Marth, C. Tags: Open access, Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Endocrine Therapy | Endometrial Cancer | France Health | General Medicine | Germany Health | Italy Health | Spain Health | Study